<?xml version="1.0" encoding="UTF-8"?>
<ref id="B82-pharmaceutics-12-00171">
 <label>82.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Steigbigel</surname>
    <given-names>R.T.</given-names>
   </name>
   <name>
    <surname>Cooper</surname>
    <given-names>D.A.</given-names>
   </name>
   <name>
    <surname>Kumar</surname>
    <given-names>P.N.</given-names>
   </name>
   <name>
    <surname>Eron</surname>
    <given-names>J.E.</given-names>
   </name>
   <name>
    <surname>Schechter</surname>
    <given-names>M.</given-names>
   </name>
   <name>
    <surname>Markowitz</surname>
    <given-names>M.</given-names>
   </name>
   <name>
    <surname>Loutfy</surname>
    <given-names>M.R.</given-names>
   </name>
   <name>
    <surname>Lennox</surname>
    <given-names>J.L.</given-names>
   </name>
   <name>
    <surname>Gatell</surname>
    <given-names>J.M.</given-names>
   </name>
   <name>
    <surname>Rockstroh</surname>
    <given-names>J.K.</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>Raltegravir with Optimized Background Therapy for Resistant HIV-1 Infection</article-title>
  <source>N. Engl. J. Med.</source>
  <year>2008</year>
  <volume>359</volume>
  <fpage>339</fpage>
  <lpage>354</lpage>
  <pub-id pub-id-type="doi">10.1056/NEJMoa0708975</pub-id>
  <?supplied-pmid 18650512?>
  <pub-id pub-id-type="pmid">18650512</pub-id>
 </element-citation>
</ref>
